Tabula Rasa HealthCare and the Trouble with One More Pill

The medicine cabinet has a curious habit: it fills up one sensible decision at a time. A prescription for one condition, another for a second, something to help with sleep. Each arrives with its own justification. The patient, however, takes the collection. Tabula Rasa HealthCare made that difference - between the individual prescription and the assembled regimen - the center of its business.

That makes this an unusual health-tech story. The interesting object is neither a new drug nor a wristband. It is a list, examined properly. And the commercial question is wonderfully awkward: who gets paid to prevent the trouble that a perfectly legitimate prescription might help create?

One prescription. Many accomplices.

MedWise, the company’s proprietary technology, looks across a medication profile. Its risk score brings together several kinds of burden: sedation, anticholinergic effects, cardiac rhythm risk, metabolic interactions and adverse-event information. A medicine can contribute to more than one. The point is to give the pharmacist a view of the gathering, rather than spend the entire evening introducing the guests in pairs.

Conventional interaction checks remain useful. Tabula Rasa’s distinction was the simultaneous, cumulative analysis of multiple drugs, followed by clinical interpretation. A score helps identify whose regimen deserves attention; the associated decision-support tools help investigate why. More information earns its keep only when it changes the next useful action.

Those actions might include a clinician considering a dose adjustment, a different medicine, closer monitoring or deprescribing. AnewHealth’s current discussion of MedWise describes exactly this practical range. It also stresses non-directive support. A computer can draw attention to a problem; it cannot know every reason a patient and clinician have for choosing a treatment.

The customer who owns the hospital bill

Calvin and Orsula Knowlton founded the business in 2009. Its early pharmacy operation, CareKinesis, was built for the Program of All-Inclusive Care for the Elderly, or PACE. The first PACE clients arrived in 2011. This was a consequential choice of audience: people with complex needs, and organizations responsible for coordinating their care.

In a capitated model, the organization receives a fixed payment and bears financial responsibility for care. An avoidable hospital visit is therefore both a patient problem and an expense the organization has reason to prevent. The case for a medication review becomes easier to explain when the buyer also feels the consequences of a medication-related complication.

Tabula Rasa sold to organizations rather than depending on patients shopping for an analytics subscription. PACE programs, health plans and risk-bearing providers needed medication expertise, delivery and administrative help. The company’s 2023 investor presentation reported more than 180 clients. Its claim that over 80% of the PACE population used at least one solution described a broad portfolio relationship, not universal use of MedWise.

The software came with a pharmacy

Calling Tabula Rasa a software company catches only part of the business. CareKinesis supplied clinical pharmacy services and medications. Pharmastar handled pharmacy benefits. Capstone offered risk-adjustment services. The wider portfolio included PACE technology and administrative support. These were different jobs sold around the same complicated customer.

The financial mix makes the point. In 2022, continuing operations generated approximately $299.5 million in revenue: $231.1 million from medications and $68.5 million from technology-enabled solutions. The latter label included services; it should not be read as a pure software-subscription figure.

That combination places the company between pharmacy operators, clinical services firms and healthcare analytics vendors. A buyer comparing alternatives has to decide which job needs doing. An in-house team may supply the judgment. A pharmacy may supply the medicines. A software vendor may supply the alerts. Tabula Rasa’s proposition joined several of those tasks, with particular expertise in complex medication regimens.

A number worth reading carefully

The science deserves attention, and a careful reading. A 2020 retrospective study examined 1,965 PACE participants. Each additional MedWise Risk Score point was associated with an 8.6% increase in the odds of an adverse drug event and $1,037 in additional annual medical spending. Association is the operative word. Lowering a score does not automatically produce that amount of savings.

A larger 2021 Medicare observational study also found relationships between elevated scores and adverse events, falls and other outcomes. These results support using the regimen to identify patients who may need attention. They leave the next question open: how much benefit comes from a particular intervention, delivered by a particular team?

“Patients shouldn’t be harmed by their medications.”Calvin H. Knowlton · March 2022

A 2022 study compared PACE participants receiving CareKinesis medication-risk services with participants receiving pharmacy services elsewhere. It reported a $5,024 average year-over-year medical-cost reduction per participant in the CareKinesis group. It was retrospective and quasi-experimental, and company-affiliated researchers were involved. This is evidence worth considering, rather than a discount voucher redeemable by every future customer.

Tabula Rasa also tested its ideas with partners. In 2021, ASHP announced a collaboration involving three large health systems. Research with Regence used simulated drug additions to examine potential risk without administering the drugs to patients. The simulation answered a modeling question; it did not establish the safety or effectiveness of those drugs in practice.

The pilot ended before the idea did

The corporate history supplies a less tidy lesson. An enhanced medication therapy management pilot ended on December 31, 2021. It had contributed $9.2 million of revenue that year. No related revenue was recognized afterward. A useful clinical approach can lose a commercial channel when the program supporting it stops.

What gave way here was a revenue stream, not a published finding that the science had failed. During the ensuing reset, Tabula Rasa sold PrescribeWellness, DoseMe and SinfoníaRx. In September 2022, a cooperation agreement with investor Indaba brought leadership and board changes, and the founders retired. Those events document the change of direction without requiring an invented account of anyone’s private epiphany.

In August 2023, the company announced a Nautic-backed acquisition and combination with ExactCare. The price was $10.50 per share in cash. The approximately $570 million enterprise value included about $262 million in net debt. It was an acquisition price, not a fresh venture round or the cost of building MedWise.

The fit was practical: medication-risk science joined a broader home-pharmacy operation. When AnewHealth launched in July 2024, ExactCare and CareKinesis kept their pharmacy names. MedWise remained part of the offering. The name on the corporate door changed more than the central clinical question.

The lesson sits between the score and the doorstep

The part another organization can copy is the sequence: start with a reliable medication profile, prioritize the people whose regimens warrant review, put the findings in front of a qualified clinician, and make follow-up somebody’s responsibility. The proprietary algorithm belongs to its owner. The discipline of connecting analysis to execution is available to anyone willing to organize the work.

That approach needs conditions. An incomplete medication list can weaken the assessment. A team without time or authority to respond may accumulate alerts instead of improvements. And savings matter differently when the organization paying for pharmacy work does not receive the financial benefit of avoided hospital care. Clinical usefulness and purchasing incentives must meet.

AnewHealth’s July 2026 account of its PACE summit still emphasized earlier risk identification and closer integration with the care team. Its September PACE Month message returned to the same embedded-pharmacist role. The current service model extends from population reports to patient-level actions and pharmacy delivery. The premise persists: the patient takes the entire regimen, so the people arranging it should see the entire picture.